Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design-of-experiments based development and in vitro evaluation of a cationic lipid-based triple adjuvanted subunit pertussis vaccine.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2025
Same author

Solid Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceuticals: A Review of Opportunities, Challenges, and Delivery Applications.

Molecular pharmaceutics·2024
Same author

HDL-Chitosan Nanoparticles for siRNA Delivery as an SR-B1 Receptor Targeted System.

Combinatorial chemistry & high throughput screening·2023
Same author

Assessing the <i>In Vivo</i> Effectiveness of Cationic Lipid Nanoparticles with a Triple Adjuvant for Intranasal Vaccination against the Respiratory Pathogen <i>Bordetella pertussis</i>.

Molecular pharmaceutics·2022
Same author

Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery.

Pharmaceutics·2021
Same author

Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis.

Bone reports·2021

Related Experiment Video

Updated: May 11, 2026

Preparation and Characterization of SDF-1&#945;-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

12.4K

Chitosan non-particulate vaccine delivery systems.

Rasim Masimov1, Ellen K Wasan1

  • 1College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques
|August 8, 2024
PubMed
Summary

Chitosan enhances vaccine delivery through its adjuvant properties and various non-particulate carriers like hydrogels and microneedles. It also serves as a valuable coating material for vaccine carriers, improving immunogenicity.

Keywords:
chitosan coatingconjugate vaccinesmicroneedlesmucosal deliverynon-particulate delivery systemsthermosensitive hydrogelsvaccine

More Related Videos

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.2K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K

Related Experiment Videos

Last Updated: May 11, 2026

Preparation and Characterization of SDF-1&#945;-Chitosan-Dextran Sulfate Nanoparticles
12:00

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

12.4K
Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.2K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K

Area of Science:

  • Biomaterials Science
  • Immunology
  • Drug Delivery

Background:

  • Chitosan is a versatile polymer widely employed in drug delivery systems.
  • Chitosan-based carriers, including nanoparticles and microparticles, are extensively researched for therapeutic and vaccine delivery.
  • Chitosan exhibits intrinsic adjuvant properties, making it suitable for vaccine applications.

Purpose of the Study:

  • To review the application of chitosan as a vaccine adjuvant.
  • To explore chitosan-based non-particulate vaccine delivery systems.
  • To discuss the benefits of chitosan as a coating material for vaccine carriers.

Main Methods:

  • Literature review focusing on chitosan's role in vaccine development.
  • Analysis of chitosan's immunogenic properties.
  • Examination of various chitosan-based delivery platforms (hydrogels, microneedles, conjugates).

Main Results:

  • Chitosan demonstrates significant potential as a vaccine adjuvant due to its inherent immunogenicity.
  • Non-particulate chitosan systems like thermosensitive hydrogels, microneedles, and conjugates offer effective vaccine delivery routes.
  • Chitosan coating enhances the performance of vaccine carriers.

Conclusions:

  • Chitosan is a promising biomaterial for advanced vaccine development.
  • Its adjuvant properties and diverse delivery formats highlight its importance in modern vaccinology.
  • Further research into chitosan-based vaccines can lead to improved immunoprophylaxis.